In 2010, Pulikkan et al. showed that miR-34a blocks myeloid proliferation by targeting E2F3 during granulopoiesis, but it is downregulated in AML with mutations affecting the CCAAT enhancer binding protein alpha (C/EBPα). The gene discussed is CEBPA; the disease is acute myeloid leukemia.